ORIC Pharmaceuticals Confirmed to Present at Major Oncology Conference
South san Francisco and San Diego-based ORIC Pharmaceuticals, Inc. will participate in the 8th Annual Jefferies Global Healthcare Conference, taking place November 19-21, 2024, in London, England. The companyS Chief Financial Officer, Dominic Piscitelli, is scheduled to present on November 20, 2024, at 10:30 AM GMT.
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on addressing resistance mechanisms in cancer treatment. The presentation at the Jefferies conference will offer an possibility to discuss the company’s progress with its two lead clinical candidates: ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) EED subunit currently in development for prostate cancer, and enozertinib (ORIC-114), a brain-penetrant EGFR inhibitor targeting exon 20 mutations, EGFR atypical mutations, and HER2 exon 20 mutations across multiple genetically defined cancers. Investors and industry stakeholders will be keenly interested in updates on these programs, as resistance to existing therapies remains a significant challenge in oncology.
Investors interested in the presentation can access a live webcast through the ORIC Pharmaceuticals website at www.oricpharma.com. Further details about ORIC Pharmaceuticals can be found on thier website, as well as on X and LinkedIn.
For inquiries, contact Dominic Piscitelli directly at dominic.piscitelli@oricpharma.com or via the general information email at info@oricpharma.com.
